Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
LEXINGTON, Mass. , Sept. 19, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced the pricing of an
View HTML
Toggle Summary Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
LEXINGTON, Mass. , Sept. 18, 2017 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced that it intends
View HTML
Toggle Summary Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial
Statistically and Clinically Significant Improvement Across Multiple Sign and Symptom EndpointsOnset of Action Observed Within One Week of TherapyPhase 2b Clinical Trial Expected to be Initiated in the First Half of 2018
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Dry Eye Disease Phase 2a Clinical Trial
LEXINGTON, Mass. , Sept. 11, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will hold a
View HTML
Toggle Summary Aldeyra Therapeutics Announces Second Quarter 2017 Financial Results
LEXINGTON, Mass. , Aug. 8, 2017 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced its financial results
View HTML
Toggle Summary Aldeyra Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference
LEXINGTON, Mass. , Aug. 3, 2017 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced that Todd C.
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2017 Financial Results
LEXINGTON, Mass. , Aug. 1, 2017 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced it will issue financial results for
View HTML
Toggle Summary Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2a Clinical Trial
LEXINGTON, Mass. , July 18, 2017 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced that the last patient has completed
View HTML
Toggle Summary Aldeyra Therapeutics to Present Novel Data on the Anti-Inflammatory Mechanism and Activity of ADX-102 at the World Congress on Inflammation 2017 Annual Meeting
LEXINGTON, Mass. , June 19, 2017 /PRNewswire/ --  Aldeyra Therapeutics, Inc.  (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehyde toxicity, today announced that novel data on the
View HTML
Toggle Summary Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing
One-Point Reduction vs. Control Component of Primary Endpoint Not Met but 0.5% ADX-102 Statistically Superior to Control and Demonstrates Late-Phase Anti-Inflammatory Activity Differentiated from Standard of Care Clear Evidence of ADX-102 Dose Response Phase 3 Clinical Testing Planned Following End of Phase 2 Discussion with Regulatory Authorities in the Second Half of 2017
View HTML